Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN9933 for Prevention of Venous Thromboembolism after Total Knee Arthroplasty
2022-501470-18-00Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 2, randomised, open-label trial of amrecibart in venous thromboembolism (VTE) (3 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Incidence of confirmed, adjudicated venous thromboembolism (VTE) through day 12 (REGN9933 vs enoxaparin). Started Apr 2023; status: completed.
02
Drugs
amrecibart
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2022-501470-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501470-18-00.